Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
Filter Results:
-
+
EP02.04 - Early Stage Non-small Cell Lung Cancer - Systemic Therapy
- Type: E-Poster
- Track: Early Stage Non-small Cell Lung Cancer - Systemic Therapy
- Presentations: 10
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP02.04-001 - Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
Author(s): Alessandro Leonetti- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 108
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.01-030 - Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
Author(s): Angelo Delmonte- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 171
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.02-048 - Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
Author(s): Federico Cappuzzo- Abstract
Loading...
-
+
P2.14 - Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
- Type: Regular Poster
- Track: Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
- Presentations: 4
- Coordinates: 8/08/2022, 17:15 - 19:15, Exhibit Hall - Hall B
-
+
P2.14-02 - TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
Author(s): Lorenza Landi- Abstract
Loading...